Pancreatic Enzyme Replacement Therapy: Shortages

The Department is aware of ongoing intermittent supply issues with pancreatic enzyme replacement therapy (PERT), including Creon capsules. Supplies of Creon and other licensed alternatives have improved in the past year, and specialist importers have sourced unlicensed stock to assist in covering the remaining gap in the market. We continue to work closely with the manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to medicines.

We have widely disseminated comprehensive guidance to healthcare professionals about these supply issues, which provide advice on how to manage patients whilst there is disruption to supply. This includes serious shortage protocols to limit prescriptions to one month’s supply to ensure equitable distribution of available supplies and that Creon remains available for those patients who need it. The Department has issued additional management advice to healthcare professionals which directs clinicians to consider the unlicensed imports when licensed stock is unavailable and includes actions for integrated care boards to have local mitigation plans in place and implemented to ensure that no patient is left without PERT.

The Department also routinely engages with the affected patient advocacy groups and charities, clinicians, and other relevant stakeholders to ensure they are kept informed on the latest supply picture and any communications issued.